Speaker(s): 

Maria Fioti, PharmD Candidate 2026, Geisinger - has nothing to disclose.

Eric Dixon  PharmD Candidate 2026, Geisinger - has nothing to disclose.

Moderator(s): 

Christopher DeFrancesco, PharmD, Clinical Pharmacist / Asst Pharmacy Residency Program Director Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

1. Describe pulmonary hypertension (PH) as a disease state, including its definition, prevalence, classifications, and pathophysiology

2. Identify risk factors for developing PH and potential complications

3. Understand parameters for diagnosis of PH, including symptoms, labs, diagnostic tests, ranking/scoring systems

4. Identify pharmacologic and non-pharmacologic treatment strategies and categorize their places in therapy

5. Be able to incorporate these recommendations into clinical practice

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Christopher DeFrancesco PharmD, RPH; Anil Singh MD; Roop Parlapalli, MD, FHM, FACP; Carolyn Chilewshi, PA-C; Emilie Detweiler, PharmD, RPh; Alexa Kerecman, CRNP; John Sacino, CPhT, and Miranda Steigler, PharmD, RPh have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None.